Hunter Cherwek, MD, of Orbis discusses summit commitments, eye care workforce training, and AI in low-resource settings.

Technician-led screening catches hidden ocular surface disease before cataract surgery and helps decide when to delay surgery ...

Duravyu missed wet AMD noninferiority twice, DAYBREAK met its end points, and optogenetics won the Nobel as son-vec posted ...

The patient was highly symptomatic despite the stable vision. Goldberg said a key takeaway for attendees was that “visual ...

Uday Devgan, MD, FACS, Jordana G. Fein, MD, MS, and Carl D. Regillo, MD, FASRS, point to IOL education, emerging retina therapies, and treatment burden.

Eye care providers urged FDA advisers to approve SYD-101, citing myopia’s lifelong risks, compounding gaps and STAR trial ...

Murtaza K. Adam, MD, reviews 3 patient cases to explore referral patterns, neovascularization after treatment, and barriers to care.

An estimated 9.6 million people in the US have diabetic retinopathy, and roughly 1 in 3 patients with diabetes miss annual ...

Carreño discusses oral protein-folding correction for RHO-adRP, early-phase trial end points and genetic eligibility.

Jordana G. Fein, MD, MS, points to agent selection, payer requirements, and real-world treatment response across 3 retina ...

Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.

A simple stool test may reveal hidden bowel disease in patients whose only symptoms are in their eyes.